Literature DB >> 25749932

Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer.

Shinji Tanaka1.   

Abstract

Accumulation of multiple genetic and/or epigenetic abnormalities is required for generation and progression of cancers, and the survival of cancer cells might depend on addiction to these abnormalities. Because disruption of such dependency on the abnormal molecules should cause the cancer cell death, so-called oncogene addiction is the rationale for molecular targeted therapy. Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is one of the most lethal malignancies in humans, and remains a challenging problem in targeted therapy compared to other malignancies such as pancreatic neuroendocrine tumor. This review summarizes the molecular pathogenesis of pancreatic cancer on the basis of the recent studies of driver mutations including chromatin remodeling factors, and promising concepts "cancer stemness" and "stromal niche" for the strategy of novel targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25749932     DOI: 10.1245/s10434-015-4463-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?

Authors:  Dimitra Grapsa; Muhammad Wasif Saif; Konstantinos Syrigos
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

2.  Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer.

Authors:  Vijay S Madamsetty; Anil Sharma; Maria Toma; Stefanie Samaniego; Audrey Gallud; Enfeng Wang; Krishnendu Pal; Debabrata Mukhopadhyay; Bengt Fadeel
Journal:  Nanomedicine       Date:  2019-03-06       Impact factor: 5.307

Review 3.  Cellular and molecular aspects of pancreatic cancer.

Authors:  A Gharibi; Y Adamian; J A Kelber
Journal:  Acta Histochem       Date:  2016-02-08       Impact factor: 2.479

4.  LRG1 in pancreatic cancer cells promotes inflammatory factor synthesis and the angiogenesis of HUVECs by activating VEGFR signaling.

Authors:  Duxiong Cai; Chunji Chen; Yexiong Su; Yan Tan; Xuyue Lin; Rong Xing
Journal:  J Gastrointest Oncol       Date:  2022-02

5.  Proteasome activity is required for the initiation of precancerous pancreatic lesions.

Authors:  Takaki Furuyama; Shinji Tanaka; Shu Shimada; Yoshimitsu Akiyama; Satoshi Matsumura; Yusuke Mitsunori; Arihiro Aihara; Daisuke Ban; Takanori Ochiai; Atsushi Kudo; Hiroshi Fukamachi; Shigeki Arii; Yoshiya Kawaguchi; Minoru Tanabe
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

6.  Interaction between NFATc2 and the transcription factor Sp1 in pancreatic carcinoma cells PaTu 8988t.

Authors:  Manuela Malsy; Bernhard Graf; Katrin Almstedt
Journal:  BMC Mol Biol       Date:  2017-08-03       Impact factor: 2.946

7.  Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.

Authors:  S Mazher Hussain; Rita G Kansal; Marcus A Alvarez; T J Hollingsworth; Abul Elahi; Gustavo Miranda-Carboni; Leah E Hendrick; Ajeeth K Pingili; Lorraine M Albritton; Paxton V Dickson; Jeremiah L Deneve; Danny Yakoub; D Neil Hayes; Michio Kurosu; David Shibata; Liza Makowski; Evan S Glazer
Journal:  Cell Oncol (Dordr)       Date:  2021-03-10       Impact factor: 6.730

8.  Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.

Authors:  Hiromitsu Ito; Shinji Tanaka; Yoshimitsu Akiyama; Shu Shimada; Rama Adikrisna; Satoshi Matsumura; Arihiro Aihara; Yusuke Mitsunori; Daisuke Ban; Takanori Ochiai; Atsushi Kudo; Shigeki Arii; Shoji Yamaoka; Minoru Tanabe
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

Review 9.  Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology.

Authors:  Shinji Tanaka
Journal:  Ann Gastroenterol Surg       Date:  2018-01-24

10.  Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.

Authors:  Syue-Ting Chen; Ting-Chun Kuo; Ying-Yu Liao; Mei-Chun Lin; Yu-Wen Tien; Min-Chuan Huang
Journal:  Oncogene       Date:  2018-07-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.